Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer Carbonate Powder QD vs Sevelamer Hydrochloride TID in CKD
NCT00268957Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2006
- Primary completion
- Mar 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevelamer carbonate in hyperphosphatemia (2 arms), sponsored by Sanofi. Primary endpoints: Change from Baseline in Serum Phosphorus at 24 weeks and Safety and Tolerability at 24 weeks. Started Jan 2006; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00268957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268957.